|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM031152570 |
| 003 |
DE-627 |
| 005 |
20231221115713.0 |
| 007 |
tu |
| 008 |
231221s1988 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0104.xml
|
| 035 |
|
|
|a (DE-627)NLM031152570
|
| 035 |
|
|
|a (NLM)3133936
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Fuse, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog
|
| 264 |
|
1 |
|c 1988
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.08.1988
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A slow-release formulation of the luteinizing hormone releasing hormone (LH-RH)analog(TAP-144-SR) was administered in 6 cases of prostatic cancer. Five were untreated cases, 3 of moderately-differentiated and 2 of poorly-differentiated cancers (four D2 and one C, NX), the other (D2) was under control by another LH-RH analog. The plasma level of luteinizing hormone and follicle stimulating hormone fell below normal, and the plasma testosterone was less than 1 ng/ml by four weeks after start of treatment. According to the National Prostatic Cancer Project Criteria, 2 of the untreated cases showed a partial response and 3 of the untreated ones showed a stable response, one of which underwent transurethral resection later. The pretreated case still continued controlled more than 4 months. No side effect was noticed
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Delayed-Action Preparations
|2 NLM
|
| 650 |
|
7 |
|a Gonadotropin-Releasing Hormone
|2 NLM
|
| 650 |
|
7 |
|a 33515-09-2
|2 NLM
|
| 650 |
|
7 |
|a Testosterone
|2 NLM
|
| 650 |
|
7 |
|a 3XMK78S47O
|2 NLM
|
| 650 |
|
7 |
|a Luteinizing Hormone
|2 NLM
|
| 650 |
|
7 |
|a 9002-67-9
|2 NLM
|
| 650 |
|
7 |
|a Follicle Stimulating Hormone
|2 NLM
|
| 650 |
|
7 |
|a 9002-68-0
|2 NLM
|
| 650 |
|
7 |
|a Acid Phosphatase
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.2
|2 NLM
|
| 650 |
|
7 |
|a Leuprolide
|2 NLM
|
| 650 |
|
7 |
|a EFY6W0M8TG
|2 NLM
|
| 700 |
1 |
|
|a Akimoto, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Akakura, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shimazaki, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Murakami, S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 34(1988), 3 vom: 15. März, Seite 555-60
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:1988
|g number:3
|g day:15
|g month:03
|g pages:555-60
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 1988
|e 3
|b 15
|c 03
|h 555-60
|